Evidence map›Paper›PMID 40096844›Full record

ArticleFundamental & clinical pharmacology2025

Second primary cancers and hormonal therapies for prostate cancer: A nested case-control study.

Lucie-Marie Scailteux, Julien Bezin, Marion Gundelwein, Julien Edeline, Emmanuel Oger, Frédéric Balusson, Antoine Pariente

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fundamental & clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lucie-Marie ScailteuxUniv Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.ORCID https://orcid.org/0000-0001-7047-9107
Julien BezinService de Pharmacologie Médicale, CHU Bordeaux ; Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Inserm, DRUGS-SAFE National Platform of Pharmacoepidemiology, University of Bordeaux, Bordeaux, France.
Marion GundelweinPharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Rennes University Hospital, Rennes, France.
Julien EdelineDepartment of Medical Oncology, CLCC Eugène Marquis, COSS (Chemistry Oncogenesis Signaling), INSERM, University Rennes, Rennes, France.
Emmanuel OgerUniv Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
Frédéric BalussonUniv Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
Antoine ParienteService de Pharmacologie Médicale, CHU Bordeaux ; Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Inserm, DRUGS-SAFE National Platform of Pharmacoepidemiology, University of Bordeaux, Bordeaux, France.

Funding

Agence Nationale de Sécurité du Médicament et des Produits de Santé
6 · The paper itself

Abstract

introduction(Pre-)clinical studies have not ruled out a potential risk of second primary cancer (SCP) under the effect of some new androgen receptor pathway inhibitors (ARPIs), especially enzalutamide (ENZ).

methodsUsing the French health reimbursement claims database (Système National des Données de Santé), we designed a case-control study nested in a 2013-2020 cohort of new users of androgen-deprivation therapy. The cases were patients with a first diagnosis of SPC, identified beyond 12 months following cohort entry and up to December 31st

resultsThe cohort comprised 147 092 patients, including 7928 cases and 78 554 controls eligible for analysis. The SPCs mainly involve the digestive organs, the urinary tract, or the lungs. Recent and short exposure to ENZ was associated with SPC: OR 1.7, 95% CI [1.2-2.4]. Recent one full year of exposure to ABI, as well as full-year plus part of the second year, was associated with SPC: OR 1.8 [1.2-2.7] and 2.3 [1.3-4.0], respectively. DISCUSSION/

conclusionSPC cases were mainly observed among recently exposed patients, which could be linked to a detection bias. The insufficient number of patients exposed over many years means that no definitive conclusions can be drawn.

Indexed as

Androgen AntagonistsAndrogen Receptor AntagonistsAntineoplastic Agents, HormonalNeoplasms, Second PrimaryPhenylthiohydantoinProstatic NeoplasmsAgedAged, 80 and overAndrostenesBenzamidesCase-Control StudiesDatabases, FactualFranceHumansMaleMiddle AgedabirateroneAndrogen AntagonistsAndrogen Receptor AntagonistsAndrostenesAntineoplastic Agents, HormonalBenzamidesenzalutamideNitrilesPhenylthiohydantoinabirateroneenzalutamidesafetysecond primary cancer

Identifiers

PMID40096844
PMCPMC11913542

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.